Literature DB >> 1520757

Toxoplasmic encephalitis in AIDS.

B J Luft1, J S Remington.   

Abstract

Involvement of the central nervous system (CNS) is common in patients with advanced disease due to human immunodeficiency virus (HIV). Symptoms range from lethargy and apathy to coma, incoordination and ataxia to hemiparesis, loss of memory to severe dementia, and focal to major motor seizures. Involvement may be closely associated with HIV infection per se, as in the AIDS dementia complex, but is frequently caused by opportunistic pathogens such as Toxoplasma gondii and Cryptococcus neoformans or malignancies such as primary lymphoma of the CNS. The clinical presentations of attendant and direct CNS involvement are remarkably non-specific and overlapping, yet a correct diagnosis is critical to successful intervention. Toxoplasmic encephalitis is one of the most common and most treatable causes of AIDS-associated pathology of the CNS. A great deal has been learned in the last 10 years about its unique presentation in the HIV-infected patient with advanced disease. Drs. Benjamin J. Luft of the State University of New York at Stony Brook and Jack S. Remington of the Stanford University School of Medicine and Palo Alto Medical Foundation's Research Institute have studied T. gondii for many years and are two of the leading experts in the field. This commentary comprises an update of their initial review (J Infect Dis 1988;157:1-6) and a presentation of the current approaches to diagnosing and managing toxoplasmic encephalitis in HIV-infected patients.

Entities:  

Mesh:

Year:  1992        PMID: 1520757     DOI: 10.1093/clinids/15.2.211

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  358 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 2.  The development and biology of bradyzoites of Toxoplasma gondii.

Authors:  L M Weiss; K Kim
Journal:  Front Biosci       Date:  2000-04-01

3.  Disruption of the Toxoplasma gondii bradyzoite-specific gene BAG1 decreases in vivo cyst formation.

Authors:  Y W Zhang; K Kim; Y F Ma; M Wittner; H B Tanowitz; L M Weiss
Journal:  Mol Microbiol       Date:  1999-01       Impact factor: 3.501

4.  Lack of utility of specific immunoglobulin G antibody avidity for serodiagnosis of reactivated toxoplasmosis in immunocompromised patients.

Authors:  B Mechain; Y J Garin; F Robert-Gangneux; J Dupouy-Camet; F Derouin
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

5.  CD8(+)-T-cell immunity against Toxoplasma gondii can be induced but not maintained in mice lacking conventional CD4(+) T cells.

Authors:  Lori Casciotti; Kenneth H Ely; Martha E Williams; Imtiaz A Khan
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 6.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 7.  Lytic cycle of Toxoplasma gondii.

Authors:  M W Black; J C Boothroyd
Journal:  Microbiol Mol Biol Rev       Date:  2000-09       Impact factor: 11.056

8.  Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.

Authors:  F Derouin; M Santillana-Hayat
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Toxoplasma gondii asexual development: identification of developmentally regulated genes and distinct patterns of gene expression.

Authors:  Michael D Cleary; Upinder Singh; Ira J Blader; Jeremy L Brewer; John C Boothroyd
Journal:  Eukaryot Cell       Date:  2002-06

10.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.